DK3536339T3 - Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab - Google Patents

Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab Download PDF

Info

Publication number
DK3536339T3
DK3536339T3 DK19162585.4T DK19162585T DK3536339T3 DK 3536339 T3 DK3536339 T3 DK 3536339T3 DK 19162585 T DK19162585 T DK 19162585T DK 3536339 T3 DK3536339 T3 DK 3536339T3
Authority
DK
Denmark
Prior art keywords
benralizumab
procedure
asthma symptoms
improving asthma
improving
Prior art date
Application number
DK19162585.4T
Other languages
English (en)
Inventor
Christine Ward
Lorin Roskos
Bing Wang
Donald Raible
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3536339T3 publication Critical patent/DK3536339T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19162585.4T 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab DK3536339T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864950P 2013-08-12 2013-08-12
EP14836392.2A EP3033103B1 (en) 2013-08-12 2014-08-07 Methods for improving asthma symptoms using benralizumab

Publications (1)

Publication Number Publication Date
DK3536339T3 true DK3536339T3 (da) 2021-12-20

Family

ID=52448839

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19162585.4T DK3536339T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK14836392.2T DK3033103T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK14836392.2T DK3033103T3 (da) 2013-08-12 2014-08-07 Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab

Country Status (18)

Country Link
US (1) US9441047B2 (da)
EP (3) EP3536339B1 (da)
JP (2) JP6803229B2 (da)
KR (1) KR102337601B1 (da)
CN (2) CN111617244A (da)
AU (3) AU2014306960B2 (da)
BR (1) BR112016002462A8 (da)
CA (1) CA2918050C (da)
DK (2) DK3536339T3 (da)
ES (2) ES2740355T3 (da)
HK (2) HK1221647A1 (da)
HU (2) HUE045402T2 (da)
MX (1) MX368474B (da)
PL (2) PL3536339T3 (da)
RU (2) RU2728578C2 (da)
SG (1) SG11201600484TA (da)
TR (1) TR201910413T4 (da)
WO (1) WO2015023508A2 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2866426T3 (es) 2013-08-12 2021-10-19 Astrazeneca Ab Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab
CA2918105C (en) 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab
CN105636607A (zh) * 2013-10-15 2016-06-01 免疫医疗有限责任公司 用于使用贝那利珠单抗治疗慢性阻塞性肺疾病的方法
WO2017077391A2 (en) 2015-11-04 2017-05-11 Astrazeneca Ab Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
US20180056018A1 (en) * 2016-08-31 2018-03-01 Cephalon, Inc. Inhalation Systems, Devices and Methods
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU690474B2 (en) 1995-09-11 1998-04-23 Kyowa Hakko Kirin Co., Ltd. Antibody againts alpha-chain of human interleukin 5 receptor
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
CA2402477A1 (en) 2000-02-15 2001-08-23 Kyowa Hakko Kogyo Co., Ltd. Eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
EP1688437A4 (en) 2003-10-08 2007-09-26 Kyowa Hakko Kogyo Kk SPECIALLY BINDING ANTIBODY COMPOSITION TO IL-5 RECEPTOR
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
AU2006299429B2 (en) 2005-10-03 2012-02-23 Xencor, Inc. Fc variants with optimized Fc receptor binding properties
NO3072525T3 (da) 2007-05-14 2018-06-30
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
US8961965B2 (en) * 2011-05-18 2015-02-24 Medimmune, Llc Methods of diagnosing and treating pulmonary diseases or disorders
MX2014004968A (es) 2011-11-01 2014-08-01 Medimmune Llc Metodos para reducir la frecuencia y la gravedad de exacerbaciones agudas de asma.
ES2866426T3 (es) 2013-08-12 2021-10-19 Astrazeneca Ab Métodos para incrementar el volumen espiratorio forzado en pacientes asmáticos que usan benralizumab
CA2918105C (en) * 2013-08-12 2023-02-28 Medimmune, Llc Methods for reducing exacerbation rates of asthma using benralizumab

Also Published As

Publication number Publication date
HK1225303A1 (zh) 2017-09-08
CA2918050A1 (en) 2015-02-19
EP3033103B1 (en) 2019-06-05
PL3033103T3 (pl) 2019-10-31
PL3536339T3 (pl) 2022-02-21
MX368474B (es) 2019-10-04
JP2016527326A (ja) 2016-09-08
HK1221647A1 (zh) 2017-06-09
AU2014306960A1 (en) 2016-02-04
CN105451761A (zh) 2016-03-30
RU2020123894A (ru) 2020-09-18
CN111617244A (zh) 2020-09-04
RU2016108734A3 (da) 2018-06-18
CA2918050C (en) 2023-10-03
MX2016001195A (es) 2016-07-21
WO2015023508A2 (en) 2015-02-19
WO2015023508A8 (en) 2015-10-15
RU2728578C2 (ru) 2020-07-30
SG11201600484TA (en) 2016-02-26
EP3988114A1 (en) 2022-04-27
EP3536339B1 (en) 2021-10-06
AU2023214323A1 (en) 2023-10-19
US20150044204A1 (en) 2015-02-12
TR201910413T4 (tr) 2019-08-21
ES2901634T3 (es) 2022-03-23
BR112016002462A2 (pt) 2017-09-12
EP3033103A4 (en) 2017-03-22
WO2015023508A3 (en) 2015-04-16
KR20160042123A (ko) 2016-04-18
EP3536339A1 (en) 2019-09-11
HUE057065T2 (hu) 2022-04-28
RU2016108734A (ru) 2017-09-19
JP2020100653A (ja) 2020-07-02
JP6803229B2 (ja) 2020-12-23
AU2020202564A1 (en) 2020-05-07
HUE045402T2 (hu) 2019-12-30
US9441047B2 (en) 2016-09-13
EP3033103A2 (en) 2016-06-22
BR112016002462A8 (pt) 2018-06-12
KR102337601B1 (ko) 2021-12-10
DK3033103T3 (da) 2019-08-05
AU2014306960B2 (en) 2020-01-16
ES2740355T3 (es) 2020-02-05

Similar Documents

Publication Publication Date Title
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK3512197T5 (da) Fremgangsmåde til kortlægning af intraprædikationsmodus
DK3225604T3 (da) Fremgangsmåde til fremstilling af flerlagsruder
DK2804548T3 (da) Apparat til okklusionsfjernelse
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK2941484T3 (da) Fremgangsmåde til at opnå immunsuppressive dendritriske celler
DK2970379T3 (da) Fremgangsmåder til forhøjelse af proteinrenhed ved anvendelse af protein a-baseret kromatografi
DK3536339T3 (da) Fremgangsmåde til forbedring af astmasymptomer ved anvendelse af benralizumab
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2870252T3 (da) Fremgangsmåder ved anvendelse af patatin
DK2849760T3 (da) Fremgangsmåder til oligonukleotid-chelatkompleks
DK2834229T3 (da) Fremgangsmåde til fremstilling af ccr3-inhibitorer
DK2872891T3 (da) Risikostratificering ved influenza
DK2872536T3 (da) Fremgangsmåde til ekstraktion af biomasse
DK3033104T3 (da) Fremgangsmåder til forøgelse af forceret eksspiratorisk volumen hos astmatikere ved anvendelse af benralizumab
DK3050961T3 (da) Fremgangsmåde til forbedring af effektiviteten ved inducering af pluripotente stamceller
DK2925854T3 (da) Fremgangsmåde til forbedring af gærstammer
DK2999478T3 (da) Dextransulfat til anvendelse ved mobilisering af celler
DK2809782T3 (da) Forbedret fremgangsmåde til fremstilling af makrokugler
DK3202769T3 (da) Fremgangsmåde til oprensning af phosphaplatinforbindelser
FI20125137A (fi) Prosessikalibraattori
DK3047025T3 (da) Fremgangsmåde til fremstilling af kappevira
DK2888219T3 (da) Fremgangsmåde til fremstilling af alkenoner
DK2938422T3 (da) Fremgangsmåde til udvinding af aromastoffer
DK2688414T3 (da) Fremgangsmåde til fremstilling af brød